Mirae Asset Global Investments Co. Ltd. Increases Stock Position in Edwards Lifesciences Corporation (NYSE:EW)

Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 15.1% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 68,013 shares of the medical research company's stock after buying an additional 8,915 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in Edwards Lifesciences were worth $4,823,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Prosperity Consulting Group LLC lifted its stake in Edwards Lifesciences by 3.6% during the 4th quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company's stock valued at $289,000 after acquiring an additional 134 shares in the last quarter. Versant Capital Management Inc raised its holdings in shares of Edwards Lifesciences by 9.3% in the first quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company's stock valued at $123,000 after purchasing an additional 145 shares during the last quarter. Kera Capital Partners Inc. lifted its position in shares of Edwards Lifesciences by 5.0% during the first quarter. Kera Capital Partners Inc. now owns 3,090 shares of the medical research company's stock valued at $224,000 after purchasing an additional 148 shares in the last quarter. Moors & Cabot Inc. lifted its position in shares of Edwards Lifesciences by 0.3% during the fourth quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company's stock valued at $4,041,000 after purchasing an additional 152 shares in the last quarter. Finally, Quadrant Capital Group LLC boosted its holdings in Edwards Lifesciences by 3.1% during the fourth quarter. Quadrant Capital Group LLC now owns 5,180 shares of the medical research company's stock worth $383,000 after purchasing an additional 156 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on EW. Wall Street Zen downgraded shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Friday, May 16th. Piper Sandler upped their target price on Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a report on Tuesday, May 13th. Dbs Bank raised Edwards Lifesciences to a "hold" rating in a research report on Monday, June 2nd. Robert W. Baird boosted their price objective on Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research report on Thursday, April 24th. Finally, Citigroup reaffirmed a "buy" rating and set a $95.00 target price (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $80.20.

Edwards Lifesciences Stock Performance

EW stock traded down $0.25 during midday trading on Thursday, reaching $76.77. 1,679,364 shares of the company's stock traded hands, compared to its average volume of 5,238,956. The firm has a market capitalization of $45.03 billion, a PE ratio of 10.97, a price-to-earnings-growth ratio of 3.87 and a beta of 1.11. The company has a 50-day moving average price of $76.07 and a two-hundred day moving average price of $73.24. Edwards Lifesciences Corporation has a 52 week low of $58.93 and a 52 week high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 4.45.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. The company had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a return on equity of 16.62% and a net margin of 75.48%. The firm's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.66 EPS. As a group, equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $75.23, for a total transaction of $673,308.50. Following the sale, the insider owned 206,900 shares of the company's stock, valued at approximately $15,565,087. This represents a 4.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the firm's stock in a transaction on Friday, May 9th. The shares were sold at an average price of $74.40, for a total transaction of $837,000.00. Following the completion of the transaction, the chief financial officer directly owned 41,098 shares of the company's stock, valued at approximately $3,057,691.20. The trade was a 21.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 40,648 shares of company stock valued at $2,998,866. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.